| 4.78 -2.05 (-30.01%) | 03-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.66 |
1-year : | 10.58 |
| Resists | First : | 7.41 |
Second : | 9.06 |
| Pivot price | 7.21 |
|||
| Supports | First : | 4.76 |
Second : | 3.96 |
| MAs | MA(5) : | 6.4 |
MA(20) : | 7.4 |
| MA(100) : | 7.97 |
MA(250) : | 7.46 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 11.3 |
D(3) : | 13.1  |
| RSI | RSI(14): 19.5 |
|||
| 52-week | High : | 9.55 | Low : | 4.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DERM ] has closed below the lower bollinger band by 24.9%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 110.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.05 - 6.09 | 6.09 - 6.13 |
| Low: | 4.7 - 4.73 | 4.73 - 4.76 |
| Close: | 4.73 - 4.79 | 4.79 - 4.83 |
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Thu, 26 Mar 2026
Journey Medical (DERM) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Thu, 26 Mar 2026
Fortress Biotech Inc Stock: Journey Medical's Strong 2025 Results Highlight Growth Potential in Derm - AD HOC NEWS
Thu, 26 Mar 2026
DERM Drops 25%: The Contradiction of a Positive Analyst Rating During Sharp Intraday Decline - Bitget
Thu, 26 Mar 2026
HC Wainwright Reaffirms Buy Rating for Journey Medical (NASDAQ:DERM) - MarketBeat
Thu, 26 Mar 2026
Journey Medical stock rating reiterated at Buy by H.C. Wainwright - Investing.com
Thu, 26 Mar 2026
Journey Medical 2025 10-K: $61.9M Revenue, $(11.4)M Net Loss - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 27 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 24.3 (%) |
| Held by Institutions | 41 (%) |
| Shares Short | 2,570 (K) |
| Shares Short P.Month | 2,480 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.98 |
| Profit Margin | -14.6 % |
| Operating Margin | -8.7 % |
| Return on Assets (ttm) | -4.6 % |
| Return on Equity (ttm) | -47.1 % |
| Qtrly Rev. Growth | 20.5 % |
| Gross Profit (p.s.) | 1.43 |
| Sales Per Share | 2.17 |
| EBITDA (p.s.) | -0.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -13.66 |
| PEG Ratio | 0 |
| Price to Book value | 4.87 |
| Price to Sales | 2.19 |
| Price to Cash Flow | -33.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|